ESR1 and breast carcinoma: T-type VGCC, CaV3.1, and CaV3.2 are blocked by NNC-55-0396, a T-type Ca2+ channel blocker, and each relevant siRNA attenuates breast cancer proliferation regardless of estrogen receptor-positive or -negative cell lines (MCF-7, MDA-MB-231, and MCF-10A) [80].